GlassScriptPhysician profile
Allison Flammang
NPI 1154760163
$5,777.60
in general payments reported to CMS, 2019-2025
32 companies · $2,405 in 2025
The $2,405 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $28.45 · 2020: $56.81 · 2021: $329 · 2022: $541 · 2023: $1,159 · 2024: $1,258 · 2025: $2,405.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,822.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,730.61 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $671.14 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $592.34 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $393.92 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $388.14 | 2021-2025 | |
| Glaxosmithkline, LLC. | $326.79 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $226.82 | 2024-2025 | Caplyta |
| Abbott Laboratories | $172.38 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.96 | 2023-2025 | Jardiance, Tradjenta |
| Otsuka America Pharmaceutical, INC. | $113.29 | 2023-2025 | Rexulti |
| Amgen INC. | $110.97 | 2020-2025 | Otezla, Repatha |
| Sanofi-Aventis U.S. LLC | $101.78 | 2022-2025 | |
| Axsome Therapeutics, INC. | $81.84 | 2025 | Auvelity, Symbravo |
| Phathom Pharmaceuticals, INC. | $72.38 | 2024-2025 | Voquezna |
| Idorsia Pharmaceuticals US INC | $71.73 | 2022-2024 | Quviviq |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $65.67 | 2023-2025 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $63.83 | 2022-2024 | Qelbree, Qelbree |
| Lundbeck LLC | $61.30 | 2024 | Rexulti |
| Biotronik Nro, INC. | $55.89 | 2025 | Prospera |
| Collegium Pharmaceutical, INC. | $55.58 | 2025 | Jornay Pm |
| Exeltis, USA INC. | $37.74 | 2023 | Slynd |
| Bayer Healthcare Pharmaceuticals INC. | $34.25 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.36 | 2024 | Xifaxan |
| Sanofi Pasteur INC. | $28.88 | 2019-2022 | |
| Tris Pharma INC | $28.71 | 2024-2025 | Dyanavel Xr |
| Viiv Healthcare Company | $28.31 | 2025 | Apretude |
| Biohaven Pharmaceutical Holding Company LTD. | $25.20 | 2022 | |
| Globus Medical, INC. | $23.31 | 2025 | Senza |
| Allergan, INC. | $20.90 | 2020 | |
| Verona Pharma, INC. | $18.80 | 2025 | Ohtuvayre |
| Takeda Pharmaceuticals U.S.A., INC. | $16.19 | 2024 | Trintellix |
| Amarin Pharma, INC. | $13.59 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allison Flammang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.